DNA methylation characteristics of primary melanomas with distinct biological behaviour

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ecsedi, Szilvia ^a,b   Hernandez Vargas, Hector ^c   Lima, Sheila C ^c   Vizkeleti, Laura ^a,b   Toth, Reka ^a   Lazar, Viktoria ^a   Koroknai, Viktoria ^a   Kiss, Timea ^a   Emri, Gabriella ^d   Herceg, Zdenko ^c   Adany, Roza ^a,b   Balazs, Margit ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; PROTEIN MYB;

ADULT; ARTICLE; BRAF GENE; BRESLOW THICKNESS; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; EYA4 GENE; FEMALE; GENE; GENE DOSAGE; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; HUMAN TISSUE; KIT GENE; MALE; MELANOMA; METASTASIS; MYB GENE; RESLOW THICKNESS; THICKNESS; ULCER; COMPARATIVE GENOMIC HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PROMOTER REGION; SKIN TUMOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901361311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096612     Document Type: Article

References (44)

1. van den Hurk K, Niessen HE, Veeck J, van den Oord JJ, van Steensel MA, et al. (2012) Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta 1826: 89-102.
2. Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 13: 679-692.
3. Wild L, Flanagan JM (2010) Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 1806: 50-57.
4. James SJ, Pogribny IP, Pogribna M, Miller BJ, Jernigan S, et al. (2003) Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr 133: 3740S-3747S. (Pubitemid 37406630)
5. Acquaviva L, Szekvolgyi L, Dichtl B, Dichtl BS, de La Roche Saint Andre C, et al. (2013) The COMPASS subunit Spp1 links histone methylation to initiation of meiotic recombination. Science 339: 215-218.
6. Hernandez-Vargas H, Ouzounova M, Le Calvez-Kelm F, Lambert MP, McKay-Chopin S, et al. (2011) Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics 6: 428-439.
7. Lima SC, Hernandez-Vargas H, Simao T, Durand G, Kruel CD, et al. (2011) Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. Epigenetics 6: 1217-1227.
8. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, et al. (2010) Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 5: e9749.
9. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95: 962-968. (Pubitemid 40089588)
10. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, et al. (2006) Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 126: 422-431. (Pubitemid 43323180)
11. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, et al. (2006) Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66: 6692-6698. (Pubitemid 44085626)
12. Liu S, Ren S, Howell P, Fodstad O, Riker AI (2008) Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 21: 545-558.
13. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH (2010) Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 130: 620-622.
14. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, et al. (2010) Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 8: 56.
15. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, et al. (2011) DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 24: 352-360.
16. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genomewide DNA methylation profiling using Infinium(R) assay. Epigenomics 1: 177-200.
17. Houseman EA, Christensen BC, Karagas MR, Wrensch MR, Nelson HH, et al. (2009) Copy number variation has little impact on bead-array-based measures of DNA methylation. Bioinformatics 25: 1999-2005.
18. Christensen BC, Houseman EA, Poage GM, Godleski JJ, Bueno R, et al. (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res 70: 5686-5694.
19. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, et al. (2011) Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 71: 2561-2571.
20. Berger MF, Garraway LA (2009) Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 23: 397-414, vii.
21. Lazar V, Ecsedi S, Vizkeleti L, Rakosy Z, Boross G, et al. (2012) Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Melanoma Res 22: 202-214.
22. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, Lazar V, et al. (2012) The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol 33: 2189-2199.
23. Rakosy Z, Ecsedi S, Toth R, Vizkeleti L, Herandez-Vargas H, et al. (2013) Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One 8: e54958.
24. Thomas NE (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16: 97-103.
25. Greshock J, Nathanson K, Medina A, Ward MR, Herlyn M, et al. (2009) Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines. Genes Chromosomes Cancer 48: 419-428.
26. Hou P, Liu D, Dong J, Xing M (2012) The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11: 286-295.
27. Gershenwald JE, Soong SJ, Balch CM (2010) 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol 17: 1475-1477.
28. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, et al. (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11: 587.
29. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
30. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572. (Pubitemid 34526173)
31. Balazs M, Ecsedi S, Vizkeleti L, Begany A (2011) Genomics of human malignant melanoma. In: Tanaka IY, editor.Breakthroughs in melanoma research. Rijeka: InTech. pp. pp. 237-263.
32. Song CX, He C (2011) The hunt for 5-hydroxymethylcytosine: the sixth base. Epigenomics 3: 521-523.
33. Lian CG, Xu Y, Ceol C, Wu F, Larson A, et al. (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150: 1135-1146.
34. Tellez CS, Shen L, Estecio MR, Jelinek J, Gershenwald JE, et al. (2009) CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19: 146-155.
35. Adjemian JZ, Howell J, Holzbauer S, Harris J, Recuenco S, et al. (2009) A clustering of immune-mediated polyradiculoneuropathy among swine abattoir workers exposed to aerosolized porcine brains, Indiana, United States. Int J Occup Environ Health 15: 331-338.
36. Sigalotti L, Covre A, Fratta E, Parisi G, Sonego P, et al. (2012) Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. J Transl Med 10: 185.
37. Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE (2006) Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer 118: 1325-1329. (Pubitemid 43185625)
38. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, et al. (2011) IL8 and Cathepsin B as Melanoma Serum Biomarkers. Int J Mol Sci 12: 1505-1518.
39. Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, et al. (2011) Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med 9: 156.
40. Liu D, Liu X, Xing M (2012) Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. Biochem Biophys Res Commun 425: 45-50.
41. Bae JM, Kim JH, Kang GH (2013) Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. Histol Histopathol.
42. van Roon EH, Boot A, Dihal AA, Ernst RF, van Wezel T, et al. (2013) BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. Clin Epigenetics 5: 2.
43. Senetta R, Paglierani M, Massi D (2012) Fluorescence in-situ hybridization analysis for melanoma diagnosis. Histopathology 60: 706-714.
44. Gerami P, Li G, Pouryazdanparast P, Blondin B, Beilfuss B, et al. (2012) A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 36: 808-817.